Osteoarthritis Gene Therapy Market size was valued at USD 7.48 billion in 2023 and is set to cross USD 20.1 billion by 2036, expanding at more than 7.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of osteoarthritis gene therapy is evaluated at USD 7.95 billion.The growth of the market can be attributed to the ease of administration, affordable pain medication and therapy, and rising incidents of osteoarthritis diseases across the globe. Moreover, it is believed that 40 to 65% of osteoarthritis includes genetic components. Additionally, significant growth in the geriatric population is also anticipated to influence the growth of the market positively. A study conducted by United Nations (UN) in 2019 stated that 703 million people are aged 65 years or over. Furthermore, a large portion of the global population showed an affirmative response toward gene therapy to treat osteoarthritis disease owing to its high effectiveness. As per a report published by Yale University, a significant surge in patients receiving gene therapy is projected to reach the number of 1.09 million over the forecast period. These factors are anticipated to boost the growth of the global osteoarthritis gene therapy market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
7.9% |
|
Base Year Market Size (2023) |
USD 7.48 billion |
|
Forecast Year Market Size (2036) |
USD 20.1 billion |
|
Regional Scope |
|
The market is segmented by drug type into NSAIDs, corticosteroids, viscosupplementation agents, and analgesics, out of which, the viscosupplementation agent segment is anticipated to hold the largest share in the global osteoarthritis gene therapy market during the forecast period, on account of the high prevalence of knee osteoarthritis in the global population in recent decades. The rising cases of knee osteoarthritis are accounted to the significant change in the lifestyle such as spending more time on PCs resulting in knee joint cartilage wearing out over time. For instance, it was observed that approximately 200 people out of 10,000 suffer from knee osteoarthritis every year globally.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Purchasing Pattern |
|
|
By Distribution Channel |
|
|
By End-User |
|
Regionally, the global osteoarthritis gene therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Europe industry is poised to hold largest revenue share by 2036, on the back of increasing geriatric population with osteoarthritis disease. Additionally, osteoarthritis is the most common disease among older people, as the joints start to loosen up and get weaker with age. As of 2019, approximately, 90 million people were 65 years old or above in the Europe region. Furthermore, multiple trials of gene therapy are in the process to be modified in the Europe region.
The global osteoarthritis gene therapy market is projected to grow in the North America region, over the forecast period owing to increasing geriatric population with osteoarthritis disease. According to a report by the Administration for Community Living (ACL), in 2019, 54.1 million people in U.S. were aged 65 and over, which was 16% of the population.
April 27, 2022: Horizon Therapeutic plc acquires the fifth rank among top companies for overall corporate reputation in the annual survey of PatientView.
April 26, 2022: Sanofi makes the announcement about merging path with McLaren Racing to boost the manufacturing quantity and its excellence standards on a world-class level.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?